Cetera Investment Advisers Sells 87 Shares of Krystal Biotech, Inc. $KRYS

Cetera Investment Advisers lessened its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 4.0% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 2,089 shares of the company’s stock after selling 87 shares during the period. Cetera Investment Advisers’ holdings in Krystal Biotech were worth $377,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in KRYS. Soleus Capital Management L.P. raised its holdings in Krystal Biotech by 65.2% during the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock worth $56,144,000 after purchasing an additional 141,400 shares during the last quarter. GAMMA Investing LLC grew its holdings in Krystal Biotech by 50,249.4% during the 1st quarter. GAMMA Investing LLC now owns 121,342 shares of the company’s stock worth $21,878,000 after acquiring an additional 121,101 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Krystal Biotech during the 4th quarter valued at $15,989,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Krystal Biotech by 16.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company’s stock valued at $79,812,000 after purchasing an additional 71,200 shares during the period. Finally, Integral Health Asset Management LLC bought a new stake in Krystal Biotech in the fourth quarter valued at about $8,616,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Down 2.6%

Shares of NASDAQ:KRYS opened at $146.30 on Tuesday. The firm has a market cap of $4.23 billion, a price-to-earnings ratio of 29.74 and a beta of 0.70. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $207.84. The company’s fifty day simple moving average is $143.61 and its 200 day simple moving average is $154.90.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.21. The company had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. Research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $240.00 target price on shares of Krystal Biotech in a report on Friday, July 25th. Guggenheim cut their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Chardan Capital restated a “buy” rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Tuesday, August 5th. Citigroup reiterated a “neutral” rating and issued a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Finally, Bank of America reduced their price target on shares of Krystal Biotech from $193.00 to $192.00 and set a “buy” rating on the stock in a research report on Tuesday, July 22nd. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $210.75.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the company’s stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the transaction, the insider owned 1,508,056 shares of the company’s stock, valued at $226,208,400. This represents a 0.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last quarter, insiders sold 49,800 shares of company stock valued at $7,487,943. Insiders own 13.70% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).